Clinical Trial Update: Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of low-dose atropine eye drops (0.01%, 0.03%, 0.05%) for reducing myopia progression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia Progression

Drugs mentioned

• Atropine eye drops (atropine)

Snippet

Sponsor: Khyber Medical College, Peshawar | Conditions: Myopia Progression, Atropine | Phase 3 | Status: COMPLETED